美国接受brentuximab vedotin治疗的复发/难治性霍奇金淋巴瘤患者的治疗模式和护理成本

数据集获取（Figshare）

• 源站标题：Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study
• DOI：10.1371/journal.pone.0180261
• 发布日期：2017-10-09
• 文件数：3 个
• 文件总体积：4.36 MB
• 源站页面：https://plos.figshare.com/articles/dataset/Treatment_patterns_and_costs_of_care_for_patients_with_relapsed_and_refractory_Hodgkin_lymphoma_treated_with_brentuximab_vedotin_in_the_United_States_A_retrospective_cohort_study/5482114

命令行下载

curl -L -o "S1 Fig.tif" "https://ndownloader.figshare.com/files/9488503"
curl -L -o "S1 Table.docx" "https://ndownloader.figshare.com/files/9488518"
curl -L -o "S2 Table.docx" "https://ndownloader.figshare.com/files/9488530"

文件清单

• S1 Fig.tif（4.21 MB）
• S1 Table.docx（80.42 KB）
• S2 Table.docx（71.42 KB）

文件总体积 4.36 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objectives
Although brentuximab vedotin (BV) has changed the management of patients with relapsed or refractory Hodgkin lymphoma (RRHL), little information is available on routine clinical practice. We identified treatment patterns and costs of care among RRHL patients in the United States (US) treated with BV.
Methods
A retrospective observational study of adults initiating BV for RRHL from 2011–2015, with ≥6 months of data prior to and following BV initiation, was conducted. Treatments were classified based on dispensations and chemotherapy administration. Median total and monthly costs were estimated based on all-cause healthcare resource use in 2015 US dollars (USD).
Results
The cohort comprised 289 patients (59% male; mean age at diagnosis, 42 years) with a mean follow-up of 250 weeks. Eleven percent had BV salvage therapy prior to ASCT, and 32% had BV for a relapse post-ASCT. 43% received treatment post-BV, most commonly allogeneic stem cell transplant (SCT) and bendamustine (both 10.2%). Median (IQR) total costs from BV initiation to censoring were 294,790 (142,110–483,360) USD; and were highest among those treated with BV prior to ASCT (up to 421,900 [300,940–778,970] USD). Median monthly costs were almost 20,000 USD per month, and up to 25,000 USD per month among those with BV and ASCT. Medications were the greatest driver of median monthly costs.
Conclusions
Median total all-cause costs were almost 300,000 USD, and median monthly costs approximately 20,000 USD, per patient treated. Patients requiring treatment following BV continue to incur high costs, highlighting the economic burden associated with managing patients in the RRHL setting.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0180261（source: https://plos.figshare.com/articles/dataset/Treatment_patterns_and_costs_of_care_for_patients_with_relapsed_and_refractory_Hodgkin_lymphoma_treated_with_brentuximab_vedotin_in_the_United_States_A_retrospective_cohort_study/5482114）。